This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2008. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

(2) See Appendix 9 for definitions of financial indicators; (4) This growth is based on 2009 Business EPS of euro 6.61, see Appendix 9 for definition

U.S. Contact: Jack Cox, 908-981-5280, Jackxsanofi-aventis

Appendices

List of appendices

The board meeting which adopted the consolidated financial statements for the year ended December 31, 2009 was held on February 9, 2010. Audit procedures on the consolidated accounts have been completed. The reports of independent registered public accounting firms will be issued after finalization of specific verifications and other procedures required for the filings of the French Document de reference and Annual report on Form 20-F with the AMF and SEC, respectively.

Appendix 1: 2009 fourth-quarter and full-year consolidated net sales by product

Change on a constant structure 2009 Change at Change basis and at Q4 constant on a constant Millions net exchange reported exchange of euros sales rates basis rates Lantus?® 763 +16.7% +8.2% +16.7% Lovenox?® 754 +8.1% +0.7% +8.1% Plavix?® 570 -11.6% -13.2% -11.6% Taxotere?® 533 +4.1% -1.5% +4.1% Aprovel?® 317 +6.9% +4.3% +6.9% Eloxatin?® 67 -80.5% -81.1% -80.5% Apidra?® 37 +30.0% +23.3% +30.0% Multaq?® 12 Flagship Products 3,053 -3.5% -8.6% -3.5% Stilnox?®/ Ambien?®/ Ambien CR?®/ Myslee?® 213 +0.4% -5.3% +0.4% Allegra?® 140 -16.4% -18.1% -16.4% Copaxone?® 118 +16.7% +15.7% +16.7% Tritace?® 101 -5.4% -9.0% -5.4% Amaryl?® 106 +5.8% +1.9% +5.8% Depakine?® 84 +6.0% 0.0% +6.0% Xatral?® 71 -4.9% -12.3% -4.9% Actonel?® 65 -22.9% -21.7% -12.3% Nasacort?® 52 -3.4% -11.9% -3.4% Other Products 1,522 -2.3% -5.3% +1.4% Consumer Health Care 405 +36.1% +28.2% +19.1% Generics 333 +253.1% +246.9% +2.1% Total Pharmaceuticals 6,263 +2.7% -1.8% -0.6% Vaccines 1,098 +64.6% +54.9% +63.0% Total 7,361 +8.9% +3.8% +5.6% Change on a constant structure Change at Change basis and at 2009 constant on a constant Millions net exchange reported exchange of euros sales rates basis rates Lantus?® 3,080 +22.5% +25.7% +22.5% Lovenox?® 3,043 +8.8% +11.1% +8.8% Plavix?® 2,623 +0.2% +0.5% +0.2% Taxotere?® 2,177 +6.1% +7.1% +6.1% Aprovel?® 1,236 +4.7% +2.8% +4.7% Eloxatin?® 957 -34.7% -28.8% -34.7% Apidra?® 137 +38.8% +39.8% +38.8% Multaq?® 25 Flagship Products 13,278 +4.6% +6.4% +4.6% Stilnox?®/ Ambien?®/ Ambien CR?®/ Myslee?® 873 -1.3% +6.2% -1.3% Allegra?® 731 -2.6% +9.8% -2.6% Copaxone?® 467 -23.8% -24.9% +20.6% Tritace?® 429 -9.2% -12.6% -9.2% Amaryl?® 416 +4.2% +9.8% +4.2% Depakine?® 329 +7.1% +2.2% +7.1% Xatral?® 296 -8.5% -7.2% -8.5% Actonel?® 264 -17.6% -20.0% -7.5% Nasacort?® 220 -11.7% -8.3% -11.7% Other Products 6078 -6.0% -6.3% -2.5% Consumer Health Care 1430 +26.8% +18.9% +8.1% Generics 1012 +198.0% +185.9% +8.7% Total Pharmaceuticals 25,823 +3.7% +4.5% +2.3% Vaccines 3,483 +19.2% +21.7% +18.9% Total 29,306 +5.3% +6.3% +4.0%

Appendix 2: 2009 fourth-quarter and full-year consolidated net sales by geographic region and product

Pharmaceuticals

Change at Change at Change at Constant Constant Constant 2009 Q4 net sales exchange United exchange Other exchange (euro million) Europe rates States rates Countries rates Lantus?® 199 +8.4% 460 +16.8% 104 +36.7% Lovenox?® 227 +6.8% 443 +9.2% 84 +6.2% Plavix?® 278 -33.9% 52* +70.0% 240 +24.1% Taxotere?® 231 +6.2% 199 +5.3% 103 -2.8% Aprovel?® 230 +0.4% 7 80 +18.3% Eloxatin?® 19 -48.7% 7 -97.4% 41 -16.0% Apidra?® 18 +28.6% 14 +15.4% 5 +100.0% Multaq?® 12 Stilnox?®/ Ambien?®/ Ambien CR?®/ Myslee?® 17 -10.0% 129 -1.4% 67 +8.3% Allegra?® 3 -25.0% 46 -41.9% 91 +11.1% Copaxone?® 115 +17.2% 3 0.0% Tritace?® 69 -12.2% 32 +13.8% Amaryl?® 21 -4.5% 3 +50.0% 82 +7.5% Depakine?® 50 0.0% 34 +16.7% Xatral?® 22 -17.9% 37 +8.1% 12 -12.5% Actonel?® 38 -32.1% 27 -3.7% Nasacort?® 8 +12.5% 37 -4.7% 7 -12.5% *Sales of active ingredient to the American joint venture managed by BMS Change at Change at Change at Constant Constant Constant 2009 net sales exchange United exchange Other exchange (euro million) Europe rates States rates Countries rates Lantus?® 767 +12.2% 1,909 +23.6% 404 +42.8% Lovenox?® 890 +13.7% 1,822 +5.3% 331 +14.8% Plavix?® 1,512 -10.4% 222* +28.5% 889 +19.3% Taxotere?® 928 +7.1% 827 +5.3% 422 +5.1% Aprovel?® 916 +2.6% 7 313 +8.6% Eloxatin?® 98 -52.4% 677 -37.2% 182 -1.6% Apidra?® 68 +40.0% 54 +27.5% 15 +87.5% Multaq?® 25 Stilnox?®/ Ambien?®/ Ambien CR?®/ Myslee?® 72 -3.9% 555 -4.8% 246 +9.1% Allegra?® 23 -20.0% 306 -15.9% 402 +13.9% Copaxone?® 454 +20.7% -100% 13 -54.8% Tritace?® 298 -8.2% 131 -11.3% Amaryl?® 83 -6.4% 9 +33.3% 324 +7.2% Depakine?® 204 +2.8% 125 +15.7% Xatral?® 93 -28.9% 147 +16.0% 56 -10.8% Actonel?® 162 -25.0% 102 -2.7% Nasacort?® 36 -2.6% 158 -15.4% 26 0.0% *Sales of active ingredient to the American joint venture managed by BMS

Vaccines

Change at Change at Change at Constant Constant Constant 2009 Q4 net sales exchange United exchange Other exchange (euro million) Europe rates States rates Countries rates Polio/Pertussis/ Hib Vaccines 20 -45.9% 141 +51.5% 83 +6.2% Influenza Vaccines* 82 +315.0% 351 +377.5% 131 +117.7% Meningitis/ Pneumonia Vaccines 5 +200.0% 54 -17.1% 15 -21.1% Adult Booster Vaccines 11 -26.7% 75 +19.1% 9 +42.9% Travel and Other Endemics Vaccines 7 +16.7% 13 -12.5% 56 +11.8% Other Vaccines 5 -84.4% 33 +11.4% 7 -28.6% * Seasonal and pandemic influenza vaccines Change at Change at Change at Constant Constant Constant 2009 net sales exchange United exchange Other exchange (euro million) Europe rates States rates Countries rates Polio/Pertussis/ Hib Vaccines 135 -12.5% 529 +56.8% 304 +5.2% Influenza Vaccines* 167 +80.9% 618 +36.2% 277 +55.7% Meningitis/ Pneumonia Vaccines 17 +63.6% 437 0.0% 84 +36.1% Adult Booster Vaccines 62 +14.8% 310 -8.5% 34 +25.0% Travel and Other Endemics Vaccines 27 -9.7% 69 -15.8% 217 +7.4% Other Vaccines 40 -11.1% 135 +13.2% 21 +11.1% * Seasonal and pandemic influenza vaccines

Appendix 3: Consolidated net sales by business segment

2009 2008 2009 2008 2009 2008 2009 2008 Q4 Q4 Q3 Q3 Q2 Q2 Q1 Q1 Millions net net net net net net net net of euros sales sales sales sales sales sales sales sales Pharmaceuticals 6,263 6,380 6,354 5,906 6,726 6,032 6,480 6,389 Vaccines 1,098 709 1,046 947 712 657 627 548 Total 7,361 7,089 7,400 6,853 7,438 6,689 7,107 6,937

Appendix 4: 2009 fourth-quarter and full-year net sales by animal health product

2009 2008 Change at Change at Q4 Q4 constant 2009 2008 constant Millions net net exchange net net exchange of dollars sales sales rates sales sales rates Frontline?® and Other fipronil 162 152 +1.1% 996 1,053 -1.5% Vaccines 242 209 +4.1% 794 790 +4.4% Avermectin 112 97 +5.6% 475 512 -4.1% Other 77 67 +6.7% 289 288 +4.3% Total 593 525 +3.9% 2,554 2,643 +0.4%

Appendix 5: Adjusted income statements excluding selected items

2009 fourth-quarter income statement

2009 as % of 2008 as % of % Millions of euros Q4 net sales Q4 net sales change Net sales 7,361 100.0% 7,089 100.0% +3.8% Other revenues 368 5.0% 367 5.2% +0.3% Cost of sales (2,225) (30.2%) (1,927) (27.2%) +15.5% Gross profit 5,504 74.8% 5,529 78.0% -0.5% Research and development expenses (1,214) (16.5%) (1,306) (18.4%) -7.0% Selling and general expenses (1,991) (27.0%) (1,945) (27.4%) +2.4% Other current operating income/expenses 19 (24) Amortization of intangibles (64) (56) Operating income “ current* 2,254 30.6% 2,198 31.0% +2.5% Restructuring costs Impairment of PP&E and intangibles Gain/loss on disposals, litigation Operating income 2,254 30.6% 2,198 31.0% +2.5% Financial expenses (99) (86) Financial income (18) (36) Income before tax and associates 2,137 29.0% 2,076 29.3% +2.9% Income tax expense (509) (559) Effective tax rate 23.8% 26.9% Share of profit/loss of associates 197 193 Net income of the Merial business held for exchange** 52 27 Minority interests (81) (110) Net income (after minority interests) 1,796 24.4% 1,627 23.0% +10.4% Average number of shares outstanding (millions) 1,307.0 1,305.1 Earnings per share (in euros) 1.37 1.25 +9.6% * Operating income before restructuring, impairment of property, plant and equipment and intangibles, gains/losses on disposals, and litigation. ** Held with a view to being exchanged under an option deal agreed with Merck that will enable the Animal Health business to be combined in a joint venture (accounting classification in accordance with IFRS 5)

2009 full-year income statement

Full- Full- year as % of year as % of % Millions of euros 2009 net sales 2008 net sales change Net sales 29,306 100.0% 27,568 100.0% +6.3% Other revenues 1,443 4.9% 1,249 4.5% +15.5% Cost of sales (7,853) (26.8%) (7,335) (26.6%) +7.1% Gross profit 22,896 78.1% 21,482 77.9% +6.6% Research and development expenses (4,583) (15.6%) (4,575) (16.6%) +0.2% Selling and general expenses (7,325) (25.0%) (7,168) (26.0%) +2.2% Other current operating income/expenses 385 203 Amortization of intangibles (220) (180) Operating income “ current* 11,153 38.1% 9,762 35.4% +14.2% Restructuring costs Impairment of PP&E and intangibles Gain/loss on disposals, litigation Operating income 11,153 38.1% 9,762 35.4% +14.2% Financial expenses (324) (335) Financial income 24 65 Income before tax and associates 10,853 37.0% 9,492 34.4% +14.3% Income tax expense (3,037) (2,755) Effective tax rate 28.0% 29.0% Share of profit/loss of associates 841 720 Net income of the Merial business held for exchange** 241 170 Minority interests (427) (441) Net income (after minority interests 8,471 28.9% 7,186 26.1% +17.9% Average number of shares outstanding (millions) 1,305.9 1,309.3 Earnings per share (in euros) 6.49 5.49 +18.2% * Operating income before restructuring, impairment of property, plant and equipment and intangibles, gains/losses on disposals, and litigation. ** Held with a view to being exchanged under an option deal agreed with Merck that will enable the Animal Health business to be combined in a joint venture (accounting classification in accordance with IFRS 5)

Appendix 6: Reconciliation of adjusted income statement excluding selected items to adjusted income statement and consolidated income statement

2009 fourth-quarter income statement

Adjusted excluding selected selected Millions of euros items items Adjusted Adjustments Consolidated Net sales 7,361 7,361 7,361 Other revenues 368 368 368 Cost of sales (2,225) (2,225) (8) (2,233) Gross profit 5,504 5,504 (8) 5,496 Research and development Expenses (1,214) (1,214) (1,214) Selling and general Expenses (1,991) (1,991) (1,991) Other current operating income/expenses 19 19 19 Amortization of intangibles (64) (64) (786) (850) Operating income “ current* 2,254 2,254 (794) 1,460 Restructuring costs (131) (131) (131) Impairment of PP&E and intangibles Gain/loss on disposals, litigation Operating income 2,254 (131) 2,123 (794) 1,329 Financial expenses (99) (99) (99) Financial income (18) (18) (18) Income before tax and associates 2,137 (131) 2,006 (794) 1,212 Income tax expense (509) 140 (369) 232 (137) Share of profit/loss of associates 197 197 (6) 191 Net income of the Merial business held for exchange 52 52 (29) 23 Minority interests (81) (81) 1 (80) 2009 net income (after minority interests) 1,796 9 1,805 (596) 1,209 2008 net income (after minority interests) 1,627 85 1,712 (1,530) 182 Change 2009 vs. 2008 (in %) +10.4% +5.4% +564.3% 2009 earnings per share (in euros)** 1.37 0.01 1.38 (0.45) 0.93 2008 earnings per share (in euros) 1.25 0.06 1.31 (1.17) 0.14 Change 2009 vs. 2008 (in %) +9.6% +5.3% +564.3% * Operating income before restructuring, impairment of property, plant and equipment and intangibles, gains/losses on disposals, and litigation ** Based on an average number of shares outstanding of 1,307 million in the fourth quarter of 2009 and 1,305.1 million in the fourth quarter of 2008

Refer to Appendix 6 for a description of 2009 fourth-quarter selected items.

The material effects of the application of purchase accounting to acquisitions, primarily that of Aventis, on the consolidated income statement were as follows:

Fourth quarter of 2009

A charge of euro 8 million arising from the workdown of inventories of companies acquired during the period remeasured at fair value.An amortization charge against intangible assets of euro 786 million.Deferred taxes of euro 232 million generated by the euro 786 million amortization charge and the workdown of inventories.In Share of profits/losses from associates (excluding Merial), a reversal of euro 6 million, mainly relating to the amortization of intangible assets (net of tax); and for Merial a reversal of euro 29 million (net of tax), mainly for the workdown of inventories.

These adjustments have no cash impact for the Group.

2009 full-year income statement

Adjusted excluding selected Selected Millions of euros items items Adjusted Adjustments Consolidated Net sales 29,306 29,306 29,306 Other revenues 1,443 1,443 1,443 Cost of sales (7,853) (7,853) (27) (7,880) Gross profit 22,896 22,896 (27) 22,869 Research and development expenses (4,583) (4,583) (4,583) Selling and general expenses (7,325) (7,325) (7,325) Other current operating income/expenses 385 385 385 Amortization of intangibles (220) (220) (3,308) (3,528) Operating income “ current* 11,153 11,153 (3,335) 7,818 Restructuring costs (1,080) (1,080) (1,080) Impairment of PP&E and intangibles (20) (20) (352) (372) Gain/loss on disposals, litigation Operating income 11,153 (1,100) 10,053 (3,687) 6,366 Financial expenses (324) (324) (324) Financial income 24 24 24 Income before tax and associates 10,853 (1,100) 9,753 (3,687) 6,066 Income tax expense (3,037) 473 (2,564) 1,200 (1,364) Share of profit/loss of associates 841 841 (27) 814 Net income of the Merial business held for exchange 241 241 (66) 175 Minority interests (427) (427) 1 (426) 2009 net income (after minority interests) 8,471 (627) 7,844 (2,579) 5,265 2008 net income (after minority interests) 7,186 (118) 7,068 (3,217) 3,851 Change 2009 vs. 2008 (in %) +17.9% +11.0% +36.7% 2009 earnings per share (in euros)** 6.49 (0.48) 6.01 (1.98) 4.03 2008 earnings per share (in euros) 5.49 (0.09) 5.40 (2.46) 2.94 Change 2009 vs. 2008 (in %) +18.2% +11.3% +37.1% * Operating income before restructuring, impairment of property, plant and equipment and intangibles, gains/losses on disposals, and litigation ** Based on average number of shares outstanding of 1,305.9 million in 2009 and 1,309.3 million in 2008

Refer to Appendix 6 for a description of selected items in 2009.

The material effects of the application of purchase accounting to acquisitions, primarily that of Aventis, on the consolidated income statement were as follows:

A charge of euro 27 million arising from the workdown of inventories of companies acquired during the period remeasured at fair value.An amortization charge of euro 3,308 million against intangible assets.Impairment losses of euro 352 million, mainly in respect of Benzaclin?®, Nasacort?® and Actonel?® in light of changes in the competitive environment.Deferred taxes of euro 1,200 million. These deferred taxes were generated by the amortization charged against intangible assets, the workdown of inventories of acquired companies, and the impairment losses.In Share of profits/losses from associates (excluding Merial), a reversal of euro 27 million, mainly relating to the amortization of intangible assets (net of tax); and for Merial, a reversal of euro 66 million, of which euro 46 million related to the workdown of inventories.

These adjustments have no cash impact for the Group.

Appendix 7: Simplified consolidated cash flow statement

euros million 2009 2008 Adjusted net income 7,844 7,068 Net income from the held-for-exchange Merial business (241) (170) Net dividends from the held-for-exchange Merial business 179 116 Depreciation, amortization and impairment of property, plant and equipment and intangibles 1,351 1,195 Net gain/loss on disposals of non-current assets, net of tax (25) (45) Other items 254 360 Operating cash flow before changes in working capital 9,362 8,524 Changes in working capital (847) (1) Net cash provided by operating activities 8,515 8,523 Acquisitions of property, plant and equipment and intangibles (1,785) (1,606) Acquisitions of investments, including assumed debt (6,334) (667) Proceeds from disposals of property, plant and equipment and intangibles (net of tax), and other items 66 119 Net cash used in investing activities (8,053) (2,154) Issuance of sanofi-aventis shares 142 51 Proceeds from sale of own shares on exercise of stock options 26 6 Repurchase of own shares (1,227) Dividends (2,878) (2,708) Other items (107) (41) Change in net debt (2,355) 2,450

Appendix 8: Simplified consolidated balance sheet

ASSETS LIABILITIES & EQUITY euros million 12/31/09 12/31/08 euros million 12/31/09 12/31/08 Equity attributable Property, plant to equityholders and equipment 7,830 6,961 of the company 48,188 44,866 Intangible assets (including goodwill) 43,480 43,423 Minority interests 258 205 Non-current financial assets, investments in associates, and deferred taxes 4,865 6,200 Total equity 48,446 45,071 Long-term debt 5,961 4,173 Provisions and other non-current Non-current assets 56,175 56,584 liabilities 8,311 7,730 Deferred tax liabilities 4,933 5,668 Inventories, accounts Receivable and other Non-current current assets 12,840 11,177 liabilities 19,205 17,571 Accounts payable Cash and cash and other current equivalents 4,692 4,226 liabilities 8,099 7,512 Short-term debt 2,866 1,833 Current assets 17,532 15,403 Current liabilities 10,965 9,345 Liabilities related to assets held for Assets held for sale sale or held for or held for exchange 6,342 exchange 1,433 Total LIABILITIES Total ASSETS 80,049 71,987 & EQUITY 80,049 71,987

Appendix 9: Definitions of non-GAAP financial indicators

Net sales at constant exchange rates

When we refer to changes in our net sales at constant exchange rates, this means that we exclude the effect of changes in exchange rates.

We eliminate the effect of exchange rates by recalculating net sales for the relevant period at the exchange rates used for the previous period.

Reconciliation of reported net sales to net sales at constant exchange rates for the fourth quarter of 2009 and 2009:

Millions of euros Q4 2009 2009 Net sales 7,361 29,306 Effect of exchange rates 360 (274) Net sales at constant exchange rates 7,721 29,032

Net sales on a constant structure basis

We eliminate the effect of changes in structure by restating prior-period net sales as follows:

by including sales from the acquired entity or product rights for a portion of the prior period equal to the portion of the current period during which we owned them, based on sales information we receive from the party from whom we make the acquisition;similarly, by excluding sales in the relevant portion of the prior period when we have sold an entity or rights to a product;for a change in consolidation method, by recalculating the prior period on the basis of the method used for the current period.

Worldwide presence of Plavix?®/Iscover?®, Avapro?®/Aprovel?®

When we refer to the worldwide presence of a product, we mean our consolidated net sales of that product, minus sales of the product to our alliance partners plus non-consolidated sales made through our alliances with Bristol-Myers Squibb on Plavix?®/Iscover?® (clopidogrel bisulfate) and Aprovel?®/Avapro?®/Karvea?® (irbesartan), based on information provided to us by our alliance partner.

Operating income “ current

We define operating income “ current as operating income before restructuring, impairment of property, plant and equipment and intangibles, gains/losses on disposals, and litigation.

Adjusted net income (see appendix 5 for a detailed reconciliation)

We define adjusted net income as accounting net income after minority interests adjusted to exclude the material after-tax impacts of (i) the application of purchase accounting to acquisitions and (ii) acquisition-related integration and restructuring costs. We believe that eliminating these impacts from net income gives investors a better understanding of the underlying economic performance of the combined Group.

The material impacts of the application of purchase accounting to acquisitions, primarily the acquisition of Aventis, are as follows:

charges arising from the remeasurement of inventories at fair value, net of tax;amortization/impairment expense generated by the remeasurement of intangible assets, net of tax;any impairment of goodwill.

Adjusted net income excluding selected items

We define selected items as accounting items reflecting significant events occurring during the period that would alter a user ™s understanding of our operational performance if they were not disclosed separately. Consequently, selected items are limited in number, unusual in nature, and involve significant amounts.

Selected items are primarily recorded in the following line items:

Restructuring costs

Restructuring costs include early retirement benefits, compensation for early termination of contracts, and rationalization costs relating to restructured sites. Asset impairment losses directly attributable to restructuring are also recorded on this line. Restructuring costs included on this line relate only to unusual and major restructuring plans.

Impairment of property, plant and equipment and intangibles

This line includes major impairment losses (other than those directly attributable to restructuring) on property, plant and equipment and intangibles, including goodwill. It also includes any reversals of such losses.

Gains and losses on disposals, and litigation

This line comprises gains and losses on major disposals of property, plant and equipment and intangible assets, and costs and provisions related to major litigation.

Income tax expense, as regards the effect of material tax disputes and any tax effects of other income or expenses that are treated as selected items.

Business Net Income

With effect from the first quarter of 2010, sanofi-aventis will publish a new key Non-Gaap indicator in response to the application of IFRS 8. This indicator business net income, will replace adjusted net income excluding selected items

Business Net Income is the consolidated net income before:

Amortization of intangiblesImpairment of intangiblesOther impacts related to acquisitions (primarily inventory step-up and impacts of purchase accounting onassociates)Major restructuring costsSignificant gains and losses on disposals of non-current assetsCosts or provisions associated with major litigationTax effect on the items listed above

Reconciliation of 2009 Business Net Income to Adjusted Net Income excluding selected items

Millions of euros 2009 % Change Adjusted Net Income excluding selected items 8,471 +17.9% Amortization of intangible assets 220 - Tax effect (62) - Business Net Income 8,629 +18.0% Adjusted EPS excluding selected items 6.49 +18.2% Business EPS 6.61 +18.2%

SOURCE sanofi-aventis